Δημοσίευση

Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

ΤίτλοςFrailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Publication TypeJournal Article
Year of Publication2017
AuthorsKonstantinidis, I. T., Chouliaras K., Levine E. A., Lee B., & Votanopoulos K. I.
JournalAnn Surg Oncol
Volume24
Issue13
Pagination3825-3830
Date Published2017 Dec
ISSN1534-4681
Λέξεις κλειδιάAdult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Cytoreduction Surgical Procedures, Female, Follow-Up Studies, Frailty, Humans, Hyperthermia, Induced, Male, Middle Aged, Morbidity, Peritoneal Neoplasms, Postoperative Complications, Prognosis, Prospective Studies, Risk Assessment, Survival Rate, Young Adult
Abstract

BACKGROUND: Frailty is increasingly being recognized as a powerful predictor of postoperative outcomes for cancer patients. This study examined the role of the modified frailty index (MFI) in predicting outcomes for patients undergoing cytoreduction (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC).METHODS: Data from National Surgical Quality Improvement Program (NSQIP) patients who underwent CRS/HIPEC between 2005 and 2014 were reviewed. The MFI, validated for use in NSQIP, was used to determine correlation between frailty and postoperative outcomes.RESULTS: The analysis included 1171 patients. The patients were divided into three groups: non-frail (MFI 0), mildly frail (MFI 1 or 2), or severely frail (MFI ≥ 3). More than 90% of patients had an MFI of 0 or 1. The MFI was 0 for 716 patients (61.1%), 1 for 373 patients (31.9%), 2 for 76 patients (6.5%), 3 for 5 patients (0.4%), and 4 for 1 patient (0.1%). Overall, grade 4 Clavien morbidity was observed in 99 patients (8.5%) and mortality in 26 patients (2.2%). For non-frail, mildly frail, and severely frail patients, worsening frailty correlated respectively with increases in grade 4 Clavien morbidity (6.7% vs. 10.9% vs. 33.3%; p = 0.004) and mortality (1.3% vs. 3.3% vs. 33.3%; p < 0.001). In the multivariate analysis, which included age of 70 years or older and albumin level of 3 or lower, frailty was the only factor that correlated with postoperative mortality: non-frail:reference, mildly frail [odds ratio (OR) 2.76, 95% confidence interval (CI) 1.14-6.73; p = 0.025], severely frail (OR 29.1, 95% CI 4-210.87; p = 0.01), age of 70 years or older (OR 1.16, 95% CI 0.34-3.93; p = 0.81), and albumin level of 3 or lower (OR 2.42, 95% CI 0.84-6.98; p = 0.1).CONCLUSIONS: Frailty is a strong predictor of major grade 4 morbidity and mortality after CRS/HIPEC. Severe frailty should be a relative contraindication to CRS/HIPEC. Frailty correlates should be a selection factor in the evaluation of all candidates for CRS/HIPEC.

DOI10.1245/s10434-017-6111-0
Alternate JournalAnn. Surg. Oncol.
PubMed ID29019118

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.